// App-Quantinova.ai

1210 : Preclinical pharmacology and repeated dose toxicity of the novel agonistic TWEAK receptor binding antibody BAY-356

Researchers

Presenter

  • Sandra Berndt

Principal Investigators

  • Christian Votsmeier

  • Ruprecht Zierz

  • Jakob Walter

  • Anna-Lena Frisk

  • Stefanie Hammer

  • Heiner Apeler

  • Bertolt Kreft

Medical Centers

  • Bayer Pharma AG, Berlin, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • TNF superfamily member 12

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved